RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $91 price target on Sarepta Therapeutics (NASDAQ: SRPT) after spending ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE